Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML-Reference-Cited by-同舟云学术

Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML

Published:2017-12-07 Issue:23 Volume:130 Page:2469-2474
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Wei Andrew H.¹^ORCID,Tiong Ing S.¹^ORCID

Affiliation:

1. Department of Clinical Haematology, Alfred Hospital, Melbourne, Australia; Australian Centre for Blood Diseases, Monash University, Melbourne, Australia

Abstract

Abstract In 2017, 4 drugs received US Food and Drug Administration marketing approval for acute myeloid leukemia (AML) treatment: targeted therapies for mutant FLT3 and IDH2, a liposomal cytarabine-daunorubicin formulation for therapy-related AML and AML with myelodysplasia-related changes, and resurgence of an antibody-drug conjugate designed to target CD33. Promising results also emerged for the BCL-2 inhibitor venetoclax combined with low-intensity therapy in older patients unfit for intensive chemotherapy. This quintet of new drugs is likely to reshape the therapeutic landscape of AML.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/23/2469/1403905/blood784066.pdf

Reference64 articles.

1. Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia;Sekeres;J Clin Oncol,2012

2. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent;Fabbro;Pharmacol Ther,1999

3. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412;Weisberg;Cancer Cell,2002

4. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation;Stone;N Engl J Med,2017

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment efficiency in patients with acute myeloid leukemia from 2019 to 2023 according to the Moscow Cancer Registry;Oncohematology;2024-09-01

2. Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies;Drug Resistance Updates;2024-05

3. Per-Residue Footprints Guided Pharmacophore Model and Pharmacokinetic Profiles for the Discovery of Potential METTL3 Inhibitors Against Myeloid Leukemia;2024-04-04

4. How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials?;Blood Cancer Journal;2024-03-26

5. Literature review and expert opinion on the treatment of high-risk acute myeloid leukemia in patients who are eligible for intensive chemotherapy;Frontiers in Oncology;2024-02-20